<DOC>
	<DOCNO>NCT02448368</DOCNO>
	<brief_summary>The purpose study determine relative bioavailability RDEA3170 capsule compare RDEA3170 tablet .</brief_summary>
	<brief_title>RDEA3170 Tablet Capsule Bioavailability Study</brief_title>
	<detailed_description />
	<criteria>Subject able understand study procedures risk involve , willing provide write informed consent first studyrelated activity . Subject body weight ≥ 50 kg ( 110 lb . ) body mass index ≥ 18 ≤ 40 kg/m2 . Subject Screening serum urate level 4 7 mg/dL . Subject free clinically significant disease medical condition , per Investigator 's judgment . Subject history suspicion kidney stone . Subject undergone major surgery within 3 month prior Screening . Subject donate blood experienced significant blood loss within 12 week prior Day 1 give plasma donation within 4 week prior Day 1 . Subject clinically unacceptable physical examination , per Investigator 's judgment . Subject clinically relevant abnormality blood pressure , heart rate , body temperature , per Investigator 's judgment . Subject Screening clinical safety laboratory parameter ( serum chemistry [ serum creatinine serum urate ] , hematology , coagulation urinalysis ) outside normal limit consider clinically significant Investigator . Subject serum creatinine value upper limit normal Screening visit . Subject clinically relevant abnormality 12lead electrocardiogram , per Investigator 's judgment . Subject history cardiac abnormality Subject swallow multiple tablet capsule . Subject receive strong moderate enzymeinducing drug product within 2 month prior Day 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>